LinkedIn




Hot Topics


National HIV/AIDS Strategy: Updated to 2020 (7-30-2015)

Posted July 30, 2015

NATIONAL HIV/AIDS STRATEGY: UPDATED TO 2020
In July 2015, the White House released the National HIV/AIDS Strategy for the United States: Updated to 2020. This Update reflects the work accomplished and the new scientific developments since the original Strategy was released in 2010.

Click here to download (PDF)

EXECUTIVE SUMMARY OF THE UPDATE
Excerpted from the official document, this is a brief synopsis of the National HIV/AIDS Strategy.
Click here to download (PDF)

EXECUTIVE ORDER
President Barack Obama issued this Executive Order releasing the National HIV/AIDS Strategy: Updated to 2020 on July 30, 2015.
Click here to view

FACT SHEET
This White House fact sheet provides a brief overview of the National HIV/AIDS Strategy: Updated to 2020. This document is ideal for use as a handout to educate others about the Strategy.
Click here to view

The following resources from AIDS.gov offer more information on the updated strategy:

 

^ Return to Top


Medicaid Update: July (7-30-2015)

Posted July 30, 2015

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the July 2015 Medicaid Update.

Please click the link below to download the current edition.

http://www.health.ny.gov/health_care/medicaid/program/update/2015/jul15_mu.pdf (PDF)

To see a list of all of the 2015 DOH Medicaid Updates, please visit http://www.health.ny.gov/health_care/medicaid/program/update/2015/index.htm

 

^ Return to Top


HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Releases Statement Regarding the START and TEMPRANO Trial Results (7-28-2015)

Posted July 28, 2015

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents has released a statement announcing a change in the rating of the Panel’s recommendation on initiation of antiretroviral therapy (ART) based on the recently published results from the START and TEMPRANO trials. Both of these randomized controlled trials demonstrated greater clinical benefits when ART is initiated in asymptomatic HIV-infected patients who started on ART at CD4 counts >500 cells/mm3 instead of waiting until CD4 counts decline. Based on these results, the Panel’s recommendation remains the same, that ART is recommended for all patients, regardless of pre-treatment CD4 count, but the strength and evidence has been changed to AI for all patients (i.e., strong recommendation, based on randomized controlled trials).

For more information, please see the Panel Statement.

 

^ Return to Top


NYS Clinical Education: Save the Date, New CME Courses and Learning Module (7-28-2015)

Posted July 28, 2015

Save the Date: Testing, Treatment, and Prevention: The Clinician’s Role in Ending the AIDS Epidemic in New York State
Friday, October 30, 2015, Snug Harbor, Staten Island, New York.

Registration opening soon. This conference is free and open to New York State medical providers. For more information, please contact Naomi Harris at naoharris@chpnet.org or 1-212-523-5954

Please visit http://ceitraining.org/events/ to view all of our upcoming events.

New CME Courses
The Clinical Education Initiative is pleased to announce the availability of two new CME courses. All courses are free and can be taken online at any time.

Please visit https://www.ceitraining.org/sp2/ today to sign-up for these training opportunities.

New Learning Module
The Clinical Education Initiative is pleased to announce the availability of a new learning module. All modules are free and can be viewed online at any time.

Please visit http://www.ceitraining.org/resources/audio-video.cfm to view all of our learning modules.

For more information, please visit http://www.ceitraining.org/

 

^ Return to Top


FDA Approves Daklinza in Combination with Sofosbuvir for HCV Genotype 3 Infection (7-24-2015)

Posted July 24, 2015

On July 24, 2015, FDA approved DAKLINZA (daclatasvir) a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection. DAKLINZA is available as a 30 mg and 60 mg tablet.

DAKLINZA is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

The recommended dosage of DAKLINZA is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DAKLINZA may be taken with or without food.

The optimal duration of DAKLINZA and sofosbuvir for patients with cirrhosis has not been established.

DAKLINZA requires dosage modifications due to drug interactions. The dosage of DAKLINZA is reduced to 30 mg once daily when coadministered with strong CYP3A inhibitors using the 30 mg tablet. The dosage of DAKLINZA is increased to 90 mg once daily using an appropriate combination of tablets (three 30 mg tablets or one 60 mg and one 30 mg tablet) when coadministered with moderate CYP3A inducers.

DAKLINZA is contraindicated in combination with drugs that strongly induce CYP3A and, thus, may lead to lower exposure and loss of efficacy of DAKLINZA.

The safety and efficacy of DAKLINZA in combination with sofosbuvir were evaluated in an open-label clinical trial (ALLY-3) of 152 treatment-naïve (n=101) and treatment-experienced (n-51) participants with chronic HCV genotype 3 infection. Most treatment-experienced subjects had failed prior treatment with peginterferon/ribavirin, but 7 subjects had been treated previously with a sofosbuvir regimen and 2 subjects with a regimen containing an investigational cyclophilin inhibitor. Participants received DAKLINZA 60 mg plus sofosbuvir 400 mg once daily for 12 weeks SVR and outcomes in subjects without SVR in ALLY-3 are shown by patient population in the table below. DAKLINZA labeling carries a Limitations of Use statement to inform prescribers that sustained virologic response rates are reduced in HCV genotype 3 infected patients with cirrhosis.

Treatment Outcomes in ALLY-3: DAKLINZA in Combination with Sofosbuvir in Subjects with HCV Genotype 3 Infection

Treatment Outcomes

Treatment-Naive
n=101

Treatment-Experienced
n=51

Total
n=152

SVR
All

90% (91/101)

86% (44/51)

89% (135/152)

    No cirrhosisa

98% (80/82)

92% (35/38)

96% (115/120)

    With cirrhosis

58% (11/19)

69% (9/13)

63% (20/32)

Outcomes for subjects without SVR

    On-treatment virologic failureb

1% (1/101)

0

0.7% (1/152)

    Relapsec

9% (9/100)

14% (7/51)

11% (16/151)

a  Includes 11 subjects with missing or inconclusive cirrhosis status.
b  One subject had quantifiable HCV RNA at end of treatment.
c  Relapse rates are calculated with a denominator of subjects with HCV RNA not detected at the end of treatment.

In an analysis of 148 subjects with available baseline resistance data in ALLY-3, virus from 52% (77/148) of subjects had baseline NS5A polymorphisms at resistance-associated positions (defined as any change from reference at NS5A amino acid positions 28, 30, 31, 58, 62, 92, or 93) identified by population sequencing. The Y93H polymorphism was detected in 9% (13/148) of subjects receiving DAKLINZA and sofosbuvir and was associated with reduced SVR12 rates (Table below). Polymorphisms detected at other NS5A resistance-associated positions were not associated with reduced SVR12 rates; these polymorphisms included M28V (n=1), A30K/S/T/V (n=14), P58R/S (n=3), and S62-any (n=66). Polymorphisms at positions associated with sofosbuvir resistance or exposure (defined as any change from reference at NS5B positions L159, S282, C316, L320, or V321) were not detected in the baseline NS5B sequence of any subject (n=150) in ALLY-3 by population-based sequencing. Phylogenetic analysis of NS5A sequences indicated that all subjects with available data (n=148) were infected with HCV subtype 3a.

SVR12 Rates in Subjects with HCV Genotype 3 with/without the Baseline NS5A Y93H Polymorphism, by Cirrhosis Status

Study Population

SVR12 with Y93H

SVR12 without Y93H

All subjects

54% (7/13)

92% (124/135)

No cirrhosisa

67% (6/9)

98% (105/107)

With cirrhosis

25% (1/4)

68% (19/28)

a  Includes 11 subjects with missing or inconclusive cirrhosis status.

Based on resistance patterns observed in cell culture replicon studies and HCV genotype 3-infected subjects, cross-resistance between daclatasvir and other NS5A inhibitors is expected. Cross-resistance between daclatasvir and other classes of direct-acting antivirals is not expected. The impact of prior daclatasvir treatment experience on the efficacy of other NS5A inhibitors has not been studied. Conversely, the efficacy of DAKLINZA in combination with sofosbuvir has not been studied in subjects who have previously failed treatment with regimens that include an NS5A inhibitor.

Safety information was available for approximately 1,900 patients with HCV treated with the recommended dose of DAKLINZA in combination with other anti-HCV drugs in clinical trials. The most common side effects of DAKLINZA with sofosbuvir were fatigue (14%), headache (14%), nausea (8%) and diarrhea (5%). All adverse reactions were mild to moderate in severity. One subject experienced a serious adverse event that was considered unrelated to DAKLINZA, and no subjects discontinued therapy for adverse events. Transient, asymptomatic lipase elevations of greater than 3 times the upper limit of normal (ULN) were observed in 2% of subjects in ALLY-3.

DAKLINZA labeling includes a WARNINGS and PRECAUTIONS statement that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is co-administered with sofosbuvir in combination with another HCV direct-acting antiviral, including DAKLINZA. Co-administration of amiodarone with DAKLINZA in combination with sofosbuvir is not recommended.

The approve product label will be available soon at http://dailymed.nlm.nih.gov/dailymed/, or at drugs@fda

Please visit http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm to read the full press announcement.

Please visit http://www.fda.gov/default.htm for more information from the FDA.

 

^ Return to Top


FDA Approves Technivie for Treatment of Chronic Hepatitis C Genotype 4 (7-24-2015)

Posted July 24, 2015

On July 24, 2015, FDA approved TECHNIVIE, a fixed-dose combination containing ombitasvir, a hepatitis C virus NS5A inhibitor; paritaprevir, a hepatitis C virus NS3/4A protease inhibitor; and ritonavir, a CYP3A inhibitor. The product is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.

TECHNIVIE in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.

TECHNIVIE is not recommended for use in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).

The recommended dosage of TECHNIVIE in adults is two tablets taken orally once daily (in the morning) with a meal without regard to fat or calorie content. TECHNIVIE is intended to be used in combination with ribavirin for 12 weeks. TECHNIVIE administered without ribavirin for 12 weeks may be considered for treatment-naïve patients who cannot take or tolerate ribavirin.

TECHNIVIE is contraindicated:

  • In patients with severe hepatic impairment due to risk of potential toxicity.
  • With drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.
  • With drugs that are moderate or strong inducers of CYP3A and may lead to reduced efficacy of TECHNIVIE.
  • In patients with known hypersensitivity to ritonavir (e.g. toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome).

The safety and efficacy of TECHNIVIE with ribavirin were evaluated in a clinical trial of 135 participants with chronic HCV genotype 4 infections without cirrhosis who were either treatment-naïve (n=86) or did not achieve a virologic response with prior treatment with pegylated interferon/ribavirin (n=49). Previous exposure to HCV direct-acting antivirals was prohibited. Ninety-one participants received TECHNIVIE with ribavirin once daily for 12 weeks. Forty-four participants received TECHNIVIE once daily without ribavirin for 12 weeks.

Results showed that 100 percent of the participants who received TECHNIVIE with ribavirin achieved a sustained virologic response. Of those who received TECHNIVIE without ribavirin, 91 percent achieved sustained virologic response.

Safety information was available for 316 participants with HCV treated with the recommended dose of TECHNIVIE in combination with other anti-HCV drugs in clinical trials. The three drugs included in TECHNIVIE are also included in Viekira Pak, previously approved for the treatment of HCV genotype 1 infection. Additional safety information for those drugs was available from the Viekira Pak trials. The most common side effects of TECHNIVIE with ribavirin were fatigue, weakness (asthenia), nausea, insomnia, itching (pruritus) and other skin reactions. The majority of adverse reactions were mild in severity. None of the subjects who received TECHNIVIE with ribavirin experienced a serious adverse reaction. None of the subjects receiving TECHNIVIE with or without ribavirin discontinued treatment due to an adverse reaction.

TECHNIVIE labeling includes a WARNINGS and PRECAUTIONS that elevations of liver enzymes to greater than five times the upper limit of normal occurred in approximately one percent of clinical trial participants. The elevations occurred more frequently in females taking contraceptives containing ethinyl estradiol. Contraceptives containing ethinyl estradiol must be discontinued prior to starting TECHNIVIE. Hepatic laboratory testing should be performed during the first four weeks of starting treatment, and as clinically indicated thereafter.

The approve product label will be available soon at http://dailymed.nlm.nih.gov/dailymed/, or at drugs@fda

Please visit http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm to read the full press announcement.

Please visit http://www.fda.gov/default.htm for more information from the FDA.

 

^ Return to Top


FDA Approves Diagnostic Test to Differentiate Between Types of HIV Infection (7-23-2015)

Posted July 23, 2015

The U.S. Food and Drug Administration approved today the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

Two major types of HIV have been identified: HIV-1 and HIV-2. HIV-1 is responsible for most HIV infections throughout the world. HIV-2 is found primarily in West Africa; however, cases of HIV-2 infection have been identified in the United States. HIV-1 and HIV-2 are similar, but distinct viruses.

The Bio-Rad BioPlex 2200 HIV Ag-Ab assay is to aid in the diagnosis of infection with HIV-1 and/or HIV-2, including acute HIV-1 infection. It may be used in adults, children two years of age and older, as well as in pregnant women. The assay may also be used to screen organ donors for HIV-1/2 when the blood specimen is collected while the donor’s heart is still beating. However, the assay is not approved for use in screening blood or plasma donors, except in urgent situations where traditional licensed blood donor screening tests are unavailable or their use is impractical.

“Today’s approval provides healthcare professionals another option for the diagnosis of HIV infections,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The ability to diagnose HIV infection early and differentiate between types of infection is important in the care of individuals as both diseases exhibit the same symptoms but progress at different rates.”

HIV antigens and antibodies appear and are detectable at different stages of the infection. Early in the infection, HIV-1 antigen can be detected prior to the development of detectable levels of HIV-1 antibodies. Acute HIV-1 infection is identified when the blood specimen is positive for HIV-1 p24 antigen but is negative for HIV-1 and HIV-2 antibodies.

The Bio-Rad BioPlex 2200 HIV Ag-Ab assay allows results of antigen and antibody detection to be reported separately. In addition to distinguishing between established HIV-1 and HIV-2 infection, reporting of distinct results helps differentiate between acute and established HIV infection respectively.

The BioPlex 2200 HIV Ag-Ab assay is intended for use with the BioPlex 2200 System, which was cleared by the FDA in 2004. The new assay is manufactured by Bio-Rad Laboratories, Inc., based in Hercules, California.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Please visit http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455813.htm to read the full press announcement.

Please visit http://www.fda.gov/default.htm for more information from the FDA.

 

^ Return to Top


OMD AIDS Institute: Quick News Update (7-23-2015)

Posted July 23, 2015

OMD SCREENSHOT – July 23, 2015

***UPCOMING ENDING THE EPIDEMIC MEETINGS***

From Blueprint to Action: Ending the Epidemic NYS Regional Discussions

  • Receive updated information about HIV/AIDS in your region/borough
  • Provide input on identified service gaps in your region/borough
  • Participate in regional/borough discussions about ending the epidemic
  • Questions? Email eoabml@health.ny.gov
  • Additional sessions will be scheduled for key populations including youth and older adults.

Regional Dates:

 

^ Return to Top


New Medscape Commentary: Working With the Active Substance User (7-22-2015)

Posted July 23, 2015

Every few months Medscape features a New York State Department of Health AIDS Institute guideline along with commentary written by clinicians who work with the HIV Clinical Guidelines Program.

The most recent guideline to be featured on Medscape is Working With the Active User with commentary written by the staff of the NYSDOH AIDS Institute HIV Clinical Guidelines Program, in collaboration with Kelly S Ramsey, MD, MPH.

To view the commentary on Medscape, please click on the following link: http://www.medscape.com/viewarticle/848319

To see the full series of hivguidelines that have posted on Medscape so far, please visit the Medscape website at: http://www.medscape.com/index/section_10155_0

Medscape Commentary Archives

 

^ Return to Top


IAS 2015 Accessing Webcasts and Abstracts Online (7-22-2015)

Posted July 22, 2015

The web casts from the IAS 2015 conference are now starting to be posted online. Abstracts are also becoming accessible after they have been presented.

Access to the online conference has for many years been an essential educational role supported by the IAS and for many people is the only way to track the advances discussed at the meeting. The webcasts also broaden the wealth of experience that is brought together for the few days of the meeting.

This year, the main way to access individual webcasts and abstracts is though the online Programme at a Glance: http://pag.ias2015.org

 

^ Return to Top


New Consumer Flowchart from Project Inform: “Getting Yourself Prepared for PrEP” (7-21-2015)

Posted July 21, 2015

Project Inform has launched a new flowchart, “Getting Yourself Prepared for PrEP,” for both consumers and health navigators to use for accessing services and covering costs related to PrEP. For consumers, the front side presents an infographic that describes the process of finding a doctor, getting a prescription for, and paying for PrEP. The back side presents information about assistance programs that can help cover the PrEP.

 

^ Return to Top


IAS 2015 Video Channel on YouTube (7-20-2015)

Posted July 20, 2015

Videos featuring IAS 2015 conference highlights as well as recorded sessions are available on the conference YouTube Channel at: https://www.youtube.com/user/iasconference/videos

Get the latest conference updates and share your thoughts and ideas through the IAS 2015 Social Media channels.

  • IAS is tweeting – @IAS_conference and @iasociety – and hope many of you will tweet along, using #IAS2015 to keep the conversation going.
  • Like IAS 2015 on Facebook – and stay in touch with the latest conference updates and developments.
  • Check IAS out on Instagram to see photos as they are happening! https://instagram.com/iasociety/
  • Tell IAS why you’re following IAS 2015 and what matters most to you. Join the IAS Conference on HIV Pathogenesis, Treatment and Prevention group on LinkedIn.

You are welcome to start new discussions and add your comments to existing threads.

 

^ Return to Top


Medicaid Update: Behavioral Health Special Edition (7-17-2015)

Posted July 17, 2015

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the Behavioral Health Special Edition of the Medicaid Update.

Please click the link below to download the current edition.

http://www.health.ny.gov/health_care/medicaid/program/update/2015/jul15_mu_speced.pdf (PDF)

To see a list of all of the 2015 DOH Medicaid Updates, please visit http://www.health.ny.gov/health_care/medicaid/program/update/2015/index.htm

 

^ Return to Top


OMD AIDS Institute: Quick News Update (7-17-2015)

Posted July 17, 2015

 

^ Return to Top


HIV Organ Policy Equity Act (HOPE Act): Policies Approved to Facilitate Organ Transplantation From HIV-Infected Donors to HIV-Infected Recipients (7-16-2015)

Posted July 16, 2015

Clinical studies on the use of organs from HIV-infected donors for HIV-infected transplant recipients may begin as early as 2016. The Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Board of Directors approved policies during a June 1–2, 2015, meeting to facilitate the transplant community’s participation in the federal HIV Organ Policy Equity Act (also known as the HOPE Act). The HOPE Act calls for study of the feasibility, effectiveness, and safety of allowing transplantable organs from HIV-infected donors to be used for HIV-infected transplant candidates. The policies allow the recovery of organs from HIV-infected donors and include patient safety measures intended to ensure that these organs are used only for transplant candidates known to be HIV infected.

The National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health, is leading the development of research criteria for transplant programs that plan to use organs from HIV-infected donors for HIV-infected transplant recipients.

More information is available at http://optn.transplant.hrsa.gov/news/board-approves-policies-to-support-hope-act-enhance-vca-transplantation.

 

^ Return to Top


New York State and New York City Health Updates: Invasive Meningococcal Disease in Men Who Have Sex With Men (7-16-2015)

Originally posted September 2012; updated July 16, 2015

June 2015:

The New York State Department of Health (NYSDOH) and New York City Department of Health and Mental Hygiene (NYC DOHMH) continue to coordinate with health departments across the country, as needed, regarding cases of serogroup C invasive meningococcal disease (IMD) among men who have sex with men (MSM). The last case of IMD among MSM in NYS occurred in NYC in December 2014 and was associated with meeting through an online website, digital application (“app”), or at a bar or party.

The Chicago Department of Public Health recently issued vaccine recommendations in response to a cluster of six confirmed cases of IMD in MSM. NYSDOH and NYC DOHMH are taking this opportunity to remind providers that the following meningococcal vaccination recommendations for MSM residing in NYS are still in effect.

  • All HIV-infected MSM who reside in NYC
  • MSM, regardless of HIV status, who reside outside of NYC but have engaged in the following risk behaviors when traveling to NYC: having regular close or intimate sexual contact with men met through an online website, digital application (“app”), or at a bar or party

Providers are strongly recommended to continue to offer vaccine to eligible patients who have not yet been vaccinated. To screen for eligibility, providers should specifically inquire about recent sexual activity with other men. HIV-infected patients are recommended to receive two doses of meningococcal conjugate vaccine; the second dose should ideally be administered 8 weeks after the first dose (minimum 6 weeks). Although many people have received one dose of meningococcal vaccine, some HIV-infected persons have not received their second dose. HIV-infected patients who have not received their second dose should be contacted to return for completion of vaccination.

Providers should be aware of early clinical and laboratory findings that might indicate meningococcal septicemia, particularly in HIV-infected MSM:

  • Petechiae. Examine areas of skin pressure zones, the palms and the soles, conjunctiva and pharynx.
  • Severe muscle or abdominal pain unexplained by an alternative etiology
  • Borderline tachycardia, tachypnea or hypotension
  • Low peripheral white blood cell count (< 5,000/mm3) with predominance of neutrophils or a subnormal platelet count (<150,000/mm3)

Previous IMD-Related Health Advisories and Alerts:

September 5, 2014: NYC 2014 Health Alert #28: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 78.1 KB)

July 18, 2014: NYC 2014 Health Alert #15: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 52.5 KB)

August 14, 2013: NYC 2013 Health Alert #31: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 82.1 KB)

March 21, 2013: NYS 2013 Health Advisory Update #1: Expanded Outbreak Response Meningococcal Vaccine Recommendations for Men Who Have Sex With Men (PDF 126 KB)

March 6, 2013: NYC 2013 Health Alert #5: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men, Expanded Vaccine Recommendations (PDF 83.9 KB)

November 29, 2012: NYC 2012 Health Alert #36: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 162 KB)

October 22, 2012: NYC 2012 Health Alert #30: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 75.5 KB)

October 4, 2012: NYS 2012 Health Advisory/NYC 2012 Health Alert #28: UPDATE: Meningococcal Vaccine Recommendations for HIV-Infected Men Who Have Sex With Men (PDF 107 KB)

September 27, 2012: NYC 2012 Health Alert #27: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 134 KB)

More Information:
Health Department Clinic Locations

If you think you might be at risk, please read the patient fact sheet

See the related Frequently Asked Questions on Invasive Meningococcal Disease (PDF)

Meningitis Information for Health Care Providers

March 22, 2013: Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2013;62(RR-2):1-22.

January 4, 2013: Notes from the Field: Serogroup C Invasive Meningococcal Disease Among Men Who Have Sex With Men — New York City, 2010–2012, Morb Mortal Wkly Rep 2013;61(51);1048.

 

^ Return to Top


An Update from HEALTHQUAL International (7-6-2015)

Posted July 6, 2015

The July 2015 issue of the HEALTHQUAL Update highlights a care coordination initiative focused on linkages and referrals for HIV-TB in the Thai Binh Province of Vietnam.

This project describes high-level coordination between provincial outpatient clinics (OPCs), the TB clinic and the provincial AIDS prevention and control center (PAC). Leadership involvement and staff buy-in increased capacity for application of improvement methods among medical staff at participating facilities, enhanced communication between clinics and led to the strengthening of documentation for patient referrals within the province.

Click here to read more

HEALTHQUAL and HIVQUAL-Namibia in AIDS – July 2015, Volume 29 – Supplement 2

This paper describes the HEALTHQUAL framework and adaptive approach to building capacity in national quality management programs in low- and middle-income countries. We present a case study from Namibia illustrating how this approach is adapted to country context.

Access the paper here

The ISQua Fellowship Programme

The ISQua Fellowship Programme is a ‘learner led’ programme that encourages participants to avail themselves of a range of learning opportunities that already exist, such as conferences; and to undertake opportunities, created by ISQua, such as webinars, case studies, debates and e-learning modules.

Learn more

For more information, please visit http://www.healthqual.org/

 

^ Return to Top


OMD AIDS Institute: Performance Data Report for 2013 eHIVQUAL Review (7-6-2015)

Posted July 6, 2015

QUICK NEWS UPDATE FROM OMD AIDS INSTITUTE – 7/6/15

  • The performance data report for the 2013 eHIVQUAL review is available here.

 

^ Return to Top


Email Announcement Archives

The HIV Clinical Guidelines Program provides subscribers with email announcements of when new guidelines are posted and existing guidelines are updated.

hivguidelines email announcement archives

hivguidelines Trends, Topics & Updates monthly mailer archives

Subscribe to hivguidelines email announcements

 

^ Return to Top


Hot Topics Archive

Please visit the Hot Topics Archive page.

^ Return to Top